VEXAS syndrome: complete molecular remission after hypomethylating therapy.
Sockel K, Götze K, Ganster C, Bill M, Georgi JA, Balaian E, Aringer M, Trautmann-Grill K, Uhlig M, Bornhäuser M, Haase D, Thiede C.
Ann Hematol. 2024 Mar;103(3):993-997. doi: 10.1007/s00277-023-05611-w. Epub 2024 Jan 12.
Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review.
He L, Li H, Wang Y, Li W, Gao L, Xu B, Hu J, He P, Pu W, Sun G, Wang Z, Han Q, Liu B, Chen H.
Front Immunol. 2024 Mar 28;15:1354613. doi: 10.3389/fimmu.2024.1354613. eCollection 2024.
Lupus Nephritis Biomarkers: A Critical Review.
Alduraibi FK, Tsokos GC.
Int J Mol Sci. 2024 Jan 9;25(2):805. doi: 10.3390/ijms25020805.
A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.
Dediu M, Zielinski C.
Breast Care (Basel). 2020 Feb;15(1):67-71. doi: 10.1159/000500620. Epub 2019 May 27.
Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report.
Zhong G, Zhang X, Guo Z, Gao Y, Zhao B, Liu X, Chen L, Qiao J, Yu C, Wang L, Li Y, Yu L.
Front Immunol. 2024 Feb 29;15:1325860. doi: 10.3389/fimmu.2024.1325860. eCollection 2024.
Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis.
Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ.
Clin Breast Cancer. 2017 Jul;17(4):245-255. doi: 10.1016/j.clbc.2016.12.010. Epub 2017 Jan 11.
Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.
Li J, Hu H, Qin G, Bai F, Wu X, Ke H, Zhang J, Xie Y, Wu Z, Fu Y, Zheng H, Gong L, Xie Z, Deng Y.
Clin Cancer Res. 2024 Jan 17;30(2):368-378. doi: 10.1158/1078-0432.CCR-23-2213.
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB.
Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S.
JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735.
Complete remission of central nervous system manifestations of IgG4-related disease with rituximab - a case report.
Sihvonen AJ, Laakso SM, Tynninen O, Saaren-Seppälä H, Löfberg M.
Ther Adv Neurol Disord. 2023 Jul 18;16:17562864231186091. doi: 10.1177/17562864231186091. eCollection 2023.
